AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10894865 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/continuous infusion doxorubicin (regimen B)
Number of subjects: 182
Study 10894865 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I-UH
Number of subjects: 182
Study 10894865 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II
Number of subjects: 182
Study 10894865 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III
Number of subjects: 182
Study 10894865 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV
Number of subjects: 182
Study 10894865 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III or IV disease, tumor-free post-induction surgery I
Number of subjects: 182
Study 10894865 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III or IV disease, complete resections
Number of subjects: 182
Study 9410281 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator inhalation (0.2 mg fenoterol)
Number of subjects: 23
Study 9410281 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 23
Study 9410281 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients unresponsive to beta‐agonist (delta FEVI <= 15%)
Number of subjects: 23
Study 1589588 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg RS 86 (cholinergic agonist)
Number of subjects: 0
Study 1589588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6747142 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase/streptodornase (SK/SD) (100 U of SK per 25 U of SD)
Number of subjects: 325
Study 6747142 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK) (375 U)
Number of subjects: 325
Study 6747142 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase/streptodornase (SK/SD)
Number of subjects: 325
Study 6747142 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 325
Study 6747142 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall-antigen battery (SK/SD, SK, Candida, Trichophyton, tetanus toxoid, purified protein derivative, coccidioidin)
Number of subjects: 325
Study 31144105 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey discussing a female surgeon
Number of subjects: 3128
Study 31144105 — intervention group
Group type: COMPARATOR
Intervention: Survey discussing a male surgeon
Number of subjects: 3128
Study 30303817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg
Number of subjects: 0
Study 30303817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27856202 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint National Committee (JNC) 7 compliant treatment with intensive BP goals (<120/80 mm Hg)
Number of subjects: 123
Study 25264877 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg)
Number of subjects: 12
Study 25264877 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan (150 mg)
Number of subjects: 12
Study 19874572 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation after blood donation
Number of subjects: 399
Study 19874572 — intervention group
Group type: COMPARATOR
Intervention: No additional iron after blood donation
Number of subjects: 399
Study 16386539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (G-1)
Number of subjects: 30
Study 16386539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (G-2)
Number of subjects: 30
Study 11784408 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help intervention to promote lower fat and higher fruit and vegetable consumption
Number of subjects: 1205
Study 11784408 — intervention group
Group type: COMPARATOR
Intervention: No materials (control group)
Number of subjects: 1205
Study 9488123 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy as a single fraction
Number of subjects: 57
Study 9488123 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy in four fractions
Number of subjects: 57
Study 9488123 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (8 Gy single fraction and 16 Gy in four fractions)
Number of subjects: 57
Study 7990083 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.25 mg/day
Number of subjects: 195
Study 7990083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 2647556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone (330 mg 3 times daily)
Number of subjects: 475
Study 2647556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (75 mg 3 times daily)
Number of subjects: 475
Study 2647556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 2647556 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated patients
Number of subjects: 475
Study 2647556 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically stable patients
Number of subjects: 475
Study 2647556 — intervention group
Group type: EXPERIMENTAL
Intervention: Deteriorating patients
Number of subjects: 475
Study 4145234 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16
Study 4145234 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 16
Study 4145234 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 16
Study 4145234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29525823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd blood stopper (ABS)
Number of subjects: 225
Study 29525823 — intervention group
Group type: EXPERIMENTAL
Intervention: Feracrylum 1% solution (FS)
Number of subjects: 225
Study 29525823 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 225
Study 26848715 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal micronutrient supplementation
Number of subjects: 1412
Study 26848715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measures below the 10th percentile
Number of subjects: 1412
Study 24786017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil fine granule 50 mg
Number of subjects: 40
Study 24786017 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil tablet 50 mg
Number of subjects: 40
Study 22941691 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic biofragmentable anastomotic ring (BAR)
Number of subjects: 134
Study 22941691 — intervention group
Group type: COMPARATOR
Intervention: Valtrac BAR (Control)
Number of subjects: 134
Study 19948079 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet enriched with fish and olive oils (UFA)
Number of subjects: 16
Study 19948079 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 16
Study 18333865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (960 mg b.i.d.; 160 mg trimethoprim and 800 mg sulfamethoxazole)
Number of subjects: 28
Study 18333865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (300 mg q.d.)
Number of subjects: 28
Study 18333865 — intervention group
Group type: COMPARATOR
Intervention: Maraviroc plus placebo
Number of subjects: 28
Study 18333865 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc plus cotrimoxazole
Number of subjects: 28
Study 18333865 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc plus tenofovir
Number of subjects: 28
Study 15940615 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 4-5 mg/kg
Number of subjects: 45
Study 15940615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12915643 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (500 mg, 250 mg, and 250 mg im testosterone esters)
Number of subjects: 17
Study 12915643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching oil-based placebo)
Number of subjects: 17
Study 10562588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 106
Study 10562588 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sterilisation (Control)
Number of subjects: 106
Study 10562588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy (Men)
Number of subjects: 106
Study 8912039 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 0
Study 8912039 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 0
Study 1836100 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor)
Number of subjects: 2220
Study 1836100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2220
Study 6137426 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 40
Study 6137426 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 40
Study 31045798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (cholecalciferol) at 14,000 IU per week
Number of subjects: 0
Study 31045798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (cholecalciferol) at 28,000 IU per week
Number of subjects: 0
Study 31045798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29119301 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 64
Study 29119301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular training (ergometer)
Number of subjects: 64
Study 29119301 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 64
Study 26919177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure (16°C)
Number of subjects: 24
Study 26919177 — intervention group
Group type: COMPARATOR
Intervention: Warm condition (23°C)
Number of subjects: 24
Study 24127243 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee confidence
Number of subjects: 100
Study 24127243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain during walking
Number of subjects: 100
Study 24127243 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported knee instability
Number of subjects: 100
Study 24127243 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps strength
Number of subjects: 100
Study 24127243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic varus-valgus joint motion during walking
Number of subjects: 100
Study 24127243 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model of pain, instability, strength, and motion
Number of subjects: 100
Study 22194501 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission mammography (PEM)
Number of subjects: 367
Study 22194501 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 367
Study 22194501 — intervention group
Group type: EXPERIMENTAL
Intervention: PEM
Number of subjects: 367
Study 22194501 — intervention group
Group type: EXPERIMENTAL
Intervention: PEM (blinded retrospective review)
Number of subjects: 367
Study 21035633 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20mg)
Number of subjects: 459
Study 21035633 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (40mg)
Number of subjects: 459
Study 17392539 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 322
Study 17392539 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (HI)
Number of subjects: 322
Study 17392539 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp) and Regular human insulin (HI)
Number of subjects: 322
Study 16392300 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 50
Study 16392300 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors (ACEIs)
Number of subjects: 50
Study 12062374 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA (1.65 g per day)
Number of subjects: 223
Study 12062374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 10214573 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON-L (Adhesion Control in a Barrier Gel)
Number of subjects: 20
Study 7890391 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent formulation (vibrio cholerae CVD 103‐HgR and Salmonella typhi Ty21a)
Number of subjects: 185
Study 7890391 — intervention group
Group type: COMPARATOR
Intervention: CVD 103‐HgR followed by two doses of killed Escherichia coli K‐12 placebo
Number of subjects: 185
Study 1982881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 9
Study 1982881 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam (15 mg)
Number of subjects: 9
Study 1982881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 9
Study 1982881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 140029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a diuretic and rauwolfia serpentina
Number of subjects: 389
Study 140029 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 389
Study 31743188 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiscope
Number of subjects: 21
Study 31743188 — intervention group
Group type: COMPARATOR
Intervention: McGrath videolaryngoscope
Number of subjects: 21
Study 28595744 — intervention group
Group type: EXPERIMENTAL
Intervention: FES+Walk
Number of subjects: 27
Study 28595744 — intervention group
Group type: COMPARATOR
Intervention: WALK
Number of subjects: 27
Study 23348842 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava (120 mg of kavalactones per day, titrated to 240 mg if non-response)
Number of subjects: 75
Study 23348842 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 75
Study 23348842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 21753154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg QD (n = 23)
Number of subjects: 67
Study 21753154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg TIW (n = 22)
Number of subjects: 67
Study 21753154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg QW (n = 22)
Number of subjects: 67
Study 21753154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg QD (loading dose for 11 days)
Number of subjects: 67
Study 19112166 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d
Number of subjects: 803
Study 19112166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study 17003947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibrocathol 5% ointment
Number of subjects: 197
Study 17003947 — intervention group
Group type: COMPARATOR
Intervention: Ointment vehicle (control)
Number of subjects: 197
Study 15267037 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (200 mg)
Number of subjects: 12
Study 15267037 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate (200 mg)
Number of subjects: 12
Study 15267037 — intervention group
Group type: COMPARATOR
Intervention: Both routes of administration
Number of subjects: 12
Study 15267037 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate
Number of subjects: 12
Study 10881461 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 322
Study 9453088 — intervention group
Group type: EXPERIMENTAL
Intervention: TSB trans-tibial prosthesis with ICEROSS system
Number of subjects: 0
Study 9453088 — intervention group
Group type: COMPARATOR
Intervention: PTB trans-tibial prosthesis
Number of subjects: 0
Study 7711417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 30
Study 7711417 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 30
Study 3273207 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow-fibre membrane oxygenator
Number of subjects: 0
Study 3273207 — intervention group
Group type: COMPARATOR
Intervention: Standard bubble oxygenator
Number of subjects: 0
Study 29165029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracker-based activity intervention (Jawbone Up24 tracker worn for ≥5 days and completed weekly calls)
Number of subjects: 35
Study 29266189 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (CLOF) 30 mg/m2/d × 5, along with cyclophosphamide (CPM), etoposide (ETOP), vincristine (VCR), and pegaspargase (experimental arm 2)
Number of subjects: 105
Study 29266189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPM), etoposide (ETOP), vincristine (VCR), and pegaspargase (experimental arm 1)
Number of subjects: 105
Study 29266189 — intervention group
Group type: COMPARATOR
Intervention: Control arm: Cyclophosphamide (CPM), cytarabine, mercaptopurine, vincristine (VCR), and pegaspargase
Number of subjects: 105
Study 29266189 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (CLOF) 20 mg/m2/d × 5 (after dose reduction due to toxicity), along with cyclophosphamide (CPM) and etoposide (ETOP)
Number of subjects: 105
Study 26438645 — intervention group
Group type: EXPERIMENTAL
Intervention: THS 2.1
Number of subjects: 28
Study 26438645 — intervention group
Group type: COMPARATOR
Intervention: CCs
Number of subjects: 28
Study 24530680 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 2292
Study 24530680 — intervention group
Group type: COMPARATOR
Intervention: XIENCE V everolimus-eluting stent (EES)
Number of subjects: 2292
Study 23268820 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction
Number of subjects: 34
Study 23268820 — intervention group
Group type: COMPARATOR
Intervention: Dual-bundle ACL reconstruction
Number of subjects: 34
Study 18583022 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER+tamsulosin
Number of subjects: 0
Study 18583022 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin
Number of subjects: 0
Study 18583022 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER
Number of subjects: 0
Study 18583022 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 17201517 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-based teen pregnancy prevention program
Number of subjects: 1136
Study 15111756 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (radical type II or III hysterectomy and lymphonodectomy) for early stage I and IIA cervical cancer
Number of subjects: 0
Study 15111756 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiation therapy or concomitant chemoradiation
Number of subjects: 0
Study 15111756 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiation (external beam radiotherapy with chemotherapy and brachytherapy)
Number of subjects: 0
Study 10743326 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized reminder leaflet
Number of subjects: 0
Study 10743326 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 0
Study 9197872 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antioxidant treatment with vitamin E (800 IU/day), vitamin C (1000 mg/day), and allopurinol (200 mg/day)
Number of subjects: 56
Study 9197872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9197872 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antioxidant treatment
Number of subjects: 56
Study 1546498 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with pyloroplasty (SPV + P)
Number of subjects: 0
Study 1546498 — intervention group
Group type: COMPARATOR
Intervention: Selective proximal vagotomy without pyloroplasty (SPV - P)
Number of subjects: 0
Study 1546498 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy (SPV)
Number of subjects: 0
Study 1546498 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with and without pyloroplasty (SPV + P and SPV - P)
Number of subjects: 0
Study 2988589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg/day
Number of subjects: 91
Study 2988589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/day
Number of subjects: 91
Study 2988589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/day
Number of subjects: 91
Study 2988589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/day
Number of subjects: 91
Study 2988589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg/day
Number of subjects: 91
Study 2988589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 3106233 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas hyperimmune globulin (n = 15)
Number of subjects: 30
Study 3106233 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 15)
Number of subjects: 30
Study 29955866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (nurse care manager support, electronic registry, academic detailing, and electronic tools)
Number of subjects: 985
Study 29955866 — intervention group
Group type: COMPARATOR
Intervention: Control (electronic tools only)
Number of subjects: 985
Study 29955866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 985
Study 29955866 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 985
Study 27890303 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 6g daily as adjunctive therapy
Number of subjects: 18
Study 27890303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26595967 — intervention group
Group type: EXPERIMENTAL
Intervention: Halotherapy (HT)
Number of subjects: 120
Study 26595967 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic therapy (MT)
Number of subjects: 120
Study 26595967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HT and MT
Number of subjects: 120
Study 24205135 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic alendronate
Number of subjects: 37
Study 24205135 — intervention group
Group type: COMPARATOR
Intervention: Branded alendronate
Number of subjects: 37
Study 24205135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both generic and branded alendronate
Number of subjects: 37
Study 20508534 — intervention group
Group type: EXPERIMENTAL
Intervention: Roman chair exercise with hips flexed at 40°
Number of subjects: 34
Study 18438806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalist-Care Coordinator (HCC) team
Number of subjects: 693